natgillin/translations-raw huggingface dataset:
At dosages ranging from 0.25 to 4 mg/kg, robenacoxib had analgesic, anti-inflammatory and anti-pyretic effects in an inflammation model with a rapid onset of action (1 h).
Pri rasponu doziranja od 0,25 do 4 mg/kg, robenakoksib imao je analgetske, protuupalne i antipiretske učinke na modelu upale s brzim nastupom djelovanja (1 h).
At doses above 200 mg, the absorption was saturated probably due to poor solubility.
Pri dozi koja je veća od 200 mg apsorpcija je saturirana, najvjerojatnije zbog loše topivosti.
At doses greater than 2 mg/kg, free aflibercept clearance was approximately 1.0 L/day with a terminal half-life of 6 days.
Pri dozama većim od 2 mg/kg klirens slobodnog aflibercepta iznosio je približno 1,0 l na dan, uz poluvijek od 6 dana.
At doses in excess of the recommended dose, observed side effects at the therapeutic dose, including seizures, are exacerbated.
Kod doza većih od preporučene, primijećene reakcije kao i kod terapijske doze, uključujući napadaje su pogoršane.
At doses of 15 mg or greater, 32 of 34 patients (94%) demonstrated a ≥50% reduction of CRK-like (CRKL) phosphorylation, a biomarker of BCR-ABL inhibition, in peripheral blood mononuclear cells.
Pri dozama od 15 mg ili većim, 32 od 34 bolesnika (94%) pokazala su redukciju od ≥50% fosforilacije CRK-like (CRKL), biomarkera za inhibiciju BCR-ABL u mononuklearnim stanicama periferne krvi.
At doses of 30 to 60 mg spinosad and 0.5 to 1 mg milbemycin oxime per kg bodyweight, lethargy, anorexia/decreased appetite, diarrhoea, pruritus, dermatitis and reddening of the skin and pinna were commonly seen.
Pri dozama od 30 do 60 mg spinosada i 0,5 do 1 mg milbemicin oksima po kg tjelesne težine, često primijećene nuspojave bile su letargija, anoreksija/smanjen tek, proljev, pruritus, dermatitis i crvenilo kože i uške.
At doses of 5 to 25 mg/day, half-life in plasma is approximately 3 hours in healthy volunteers and ranges from 3 to 5 hours in patients with multiple myeloma, myelodysplastic syndromes or mantle cell lymphoma.
Pri dozama od 5 do 25 mg/dan, poluvijek u plazmi iznosi približno 3 sata u zdravih dobrovoljaca i kreće se u rasponu od 3 do 5 sati u bolesnika s multiplim mijelomom, mijelodisplastičnim sindromima ili limfomom plaštenih stanica.
At doses of 5 to 25 mg/day, half-life in plasma is approximately 3 hours in healthy volunteers and ranges from 3 to 5 hours in patients with multiple myeloma, myelodysplastic syndromes or mantle cell lymphoma..
Pri dozama od 5 do 25 mg/dan, poluvijek u plazmi iznosi približno 3 sata u zdravih dobrovoljaca i kreće se u rasponu od 3 do 5 sati u bolesnika s multiplim mijelomom, mijelodisplastičnim sindromima ili limfomom plaštenih stanica.
At doses used for prophylaxis of venous thromboembolism, enoxaparin sodium does not influence bleeding time and general blood clotting parameters, nor does it affect platelet aggregation or binding of fibrinogen to platelets.
U dozama u kojima se koristi za profilaksu venske tromboembolije, enoksaparin-natrij ne utječe na vrijeme krvarenja i opće parametre zgrušavanja krvi, niti utječe na agregaciju trombocita ili vezivanje fibrinogena na trombocite.
At doses used for prophylaxis of venous thromboembolism, enoxaparin sodium does not influence bleeding time and general blood clotting parameters, nor does it affect platelet aggregation or binding of fibrinogen to platelets.
U dozama u kojima se koristi za profilaksu venske tromboembolije, enoksaparinnatrij ne utječe na vrijeme krvarenja i opće parametre zgrušavanja krvi, niti utječe na agregaciju trombocita ili vezivanje fibrinogena na trombocite.
At doses which were low enough to maintain gestation in the animal species, no teratogenic effects were observed.
Pri dozama koje su bile dovoljno niske za održavanje gestacije životinjskih vrsta nije opažen teratogeni učinak .
At doses  25 mg apixaban displays dissolution limited absorption with decreased bioavailability.
Pri dozama od  25 mg apsorpcija apiksabana ograničena je razgradnjom te je i bioraspoloživost manja.
At each of the three monthly assessments all subjects completed a Premature Ejaculation Profile (PEP) questionnaire relating to perceived control over ejaculation, personal distress related to ejaculation, satisfaction with sexual intercourse, and interpersonal difficulty relating to ejaculation.
Na kraju svakog od tri mjesečna ocjenjivanja svi su ispitanici ispunili upitnik za određivanje profila preuranjene ejakulacije (Premature Ejaculation Profil, PEP) koji se odnosio na percipiranu kontrolu nad ejakulacijom osobnu tjeskobu povezanu s ejakulacijom, zadovoljstvo spolnim odnosom i interpersonalne teškoće povezane s ejakulacijom.
At each spot, part the coat until the skin is visible.
Na svakom mjestu razmaknite dlaku da koža bude vidljiva.
At each step, the increase or reduction in dose should be of 25 IU/kg 3 times per week.
U svakom koraku, povećanje ili smanjenje doze treba iznositi 25 IU/kg 3 puta na tjedan.
At end of study and in the combined protocols, the efficacy of Gardasil against HPV 6-, 11-, 16-, 18-related CIN 1 was 95.9 % (95% CI: 91.4, 98.4), the efficacy of Gardasil against HPV 6-, 11-, 16-, 18-related CIN (1, 2, 3) or AIS was 96.0% (95% CI: 92.3, 98.2), the efficacy of Gardasil against HPV 6-, 11-, 16-, 18-related VIN2/3 and VaIN 2/3 was 100% (95% CI: 67.2, 100) and 100% (95% CI: 55.4, 100), respectively, the efficacy of Gardasil against HPV 6-, 11-, 16-, 18-related genital warts was 99.0% (95% CI: 96.2, 99.9).
Na kraju ispitivanja i u kombiniranim protokolima; djelotvornost cjepiva Gardasil protiv CIN-a 1 povezanog s HPV-om tipova 6, 11, 16 i 18 iznosila je 95,9 % (95% CI: 91,4; 98,4), djelotvornost cjepiva Gardasil protiv CIN-a (1, 2, 3) ili AIS-a povezanih s HPV-om tipova 6, 11, 16 i 18 iznosila je 96,0% (95% CI: 92,3; 98,2), djelotvornost cjepiva Gardasil protiv VIN-a 2/3 povezanog s HPV-om tipova 6, 11, 16 i 18 iznosila je 100% (95% CI: 67,2; 100) i za VaIN-a 2/3 povezanog s istim tipovima virusa 100% (95% CI: 55,4; 100), djelotvornost cjepiva Gardasil protiv genitalnih bradavica povezanih s HPV-om tipova 6, 11, 16 i 18 iznosila je 99,0% (95% CI: 96,2; 99,9).
At end of study and in the combined protocols, the efficacy of Silgard against HPV 6-, 11-, 16-, 18-related CIN 1 was 95.9 % (95% CI: 91.4, 98.4), the efficacy of Silgard against HPV 6-, 11-, 16-, 18-related CIN (1, 2, 3) or AIS was 96.0% (95% CI: 92.3, 98.2), the efficacy of Silgard against HPV 6-, 11-, 16-, 18-related VIN2/3 and VaIN 2/3 was 100% (95% CI: 67.2, 100) and 100% (95% CI: 55.4, 100), respectively, the efficacy of Silgard against HPV 6-, 11-, 16-, 18-related genital warts was 99.0% (95% CI: 96.2, 99.9).
Na kraju ispitivanja i u kombiniranim protokolima; djelotvornost cjepiva Silgard protiv CIN-a 1 povezanog s HPV-om tipova 6, 11, 16 i 18 iznosila je 95,9 % (95% CI: 91,4; 98,4), djelotvornost cjepiva Silgard protiv CIN-a (1, 2, 3) ili AIS-a povezanih s HPV-om tipova 6, 11, 16 i 18 iznosila je 96,0% (95% CI: 92,3; 98,2), djelotvornost cjepiva Silgard protiv VIN-a 2/3 povezanog s HPV-om tipova 6, 11, 16 i 18 iznosila je 100% (95% CI: 67,2; 100) i za VaIN-a 2/3 povezanog s istim tipovima virusa 100% (95% CI: 55,4; 100), djelotvornost cjepiva Silgard protiv genitalnih bradavica povezanih s HPV-om tipova 6, 11, 16 i 18 iznosila je 99,0% (95% CI: 96,2; 99,9).
At end of study, individuals enrolled in the two Phase-III studies (Protocol- 013 and Protocol-015), were followed for up to 4 years (median 3.7 years).
Na kraju ispitivanja, ispitanici uključeni u dva ispitivanja III faze (protokoli 013 i 015) praćeni su do 4 godine (medijan 3,7 godina).
At five years after the initial injection of Xiapex, 92.8% and 93.4% of subjects were seropositive for anti-AUX-I and anti-AUX-II respectively.
Pet godina nakon prve injekcije Xiapexa 92,8% ispitanika bilo je seropozitivno na anti-AUX-I, a 93,4% na anti- AUX-II protutijela.
At four weeks postvaccination, the VZV- specific immune responses following concomitant use were not similar to the VZV-specific immune responses following nonconcomitant administration.
Četiri tjedna nakon cijepljenja, specifični imunološki odgovor protiv virusa varicella-zoster nastao nakon istodobne primjene nije bio sličan specifičnom imunološkom odgovoru protiv virusa varicella-zoster kad se ne primjenjuje istodobno.
At fourteen days after administration, urine concentrations were 2.9 μg/ml.
Četrnaesti dan nakon primjene koncentracije u urinu bile su 2,9 g/ml.
At high doses (≥1,000 mg/kg/day) rats exhibited prolongation of gestation and reduction in foetal viability.
U štakora je kod primjene visokih doza (≥1000 mg/kg/dan) primijećeno produženje gestacije i smanjenje sposobnosti preživljenja ploda.
At high doses (≥450 mg/kg/day) rats exhibited a prolongation of oestrous cycle and a high incidence of irregular cycles.
Pri visokim su dozama (≥450 mg/kg/dan) u štakora zabilježeni produženje estrusnog ciklusa i visoka incidencija nepravilnih ciklusa.
At high serum concentrations of dexmedetomidine sedation is not increased although the level of analgesia does increase with further dose increases.
Pri visokim serumskim koncentracijama deksmedetomidina sedacija se ne povećava, iako se razina analgezije povećava s daljnjim povećanjima doze.
At higher doses rivaroxaban displays dissolution limited absorption with decreased bioavailability and decreased absorption rate with increased dose.
Pri većim dozama rivaroksaban pokazuje apsorpciju ograničenu otapanjem uz smanjenu bioraspoloživost i smanjenu brzinu apsorpcije s povećanjem doze.
At higher doses rivaroxaban displays dissolution limited absorption with decreased bioavailability and decreased absorption rate with increased dose.
Pri većim dozama rivaroksaban pokazuje apsorpciju ograničenu otapanjem, uz smanjenu bioraspoloživost i smanjenu brzinu apsorpcije s povećanjem doze.
At higher doses, it can help to adjust an abnormal immune system and modulate the immune response.
U većim dozama može pomoći pri podešavanju abnormalnog imunosnog sustava i modulaciji imunosnog odgovora.
At higher doses, ritonavir acts as a ‘protease inhibitor’.
U većim dozama ritonavir djeluje kao "inhibitor proteaze".
At higher oral doses, Cmax and AUC increase less than proportionally to the dose.
Kod viših doza, Cmax i AUC povećavaju se manje nego proporcionalno dozi.
At hospital, activated charcoal can be administered if the patient’s airways can be adequately protected.
Bolničko osoblje može dati bolesniku aktivni ugljen ako mu je na primjeren način zaštitilo dišne putove.
At initiation of Ventavis treatment the first inhaled dose should be 2.5 microgram iloprost as delivered at the mouthpiece of the nebuliser.
Na početku liječenja lijekom Ventavis, prva doza koja se inhalira je 2,5 mikrograma iloprosta dostavljena putem nastavka atomizatora za usta.
At least 1 adverse reaction of any toxicity grade was reported for 848 (97.5%) patients.
Najmanje jedna nuspojava bilo kojeg stupnja toksičnosti bila je prijavljena u 848 (97,5%) bolesnika.
At least 1 day,
Najmanje 1 dan
At least 1 day,
Najmanje 1 dan sve dok epizoda
At least 1 day, until the
Najmanje 1 dan,
At least 1 day, until the bleeding episode as indicated by pain is resolved or healing is achieved.
1 dan dok ne prestanu bolovi ili dok ne dođe do zacjeljivanja.
At least 1 Grade 3 or Grade 4 adverse reaction was reported for 531 (61.0%) patients.
Najmanje jedna nuspojava 3. stupnja ili 4. stupnja prijavljena je u 531 (61,0%) bolesnika.
At least 1 mutation
Najmanje jedna mutacija
at least 10 to < 15 kg
Najmanje 10 do < 15 kg
At least 14 days before you start treatment with Soliris, your doctor will administer a vaccine against meningitis if it was not previously administered or if your vaccination is outdated.
Najmanje 14 dana prije nego što počnete liječenje lijekom Soliris, liječnik će Vas cijepiti protiv meningitisa ako ga već prije niste primili ili ako je prošlo previše vremena od cijepljenja.
At least 14 days should elapse between discontinuation of MAOI and initiation of treatment with naltrexone / bupropion (see section 4.5)
Mora proći najmanje 14 dana između prekida MAOI-a i započinjanja liječenja s naltrekson / bupropionom (vidjeti dio 4.5)
at least 15 to < 25 kg
Najmanje 15 do < 25 kg
at least 2 hours after any food; then wait 1 hour before eating again.
najmanje 2 sata nakon bilo koje hrane; onda pričekajte 1 sat prije sljedećeg obroka.
at least 25 to < 35 kg
Najmanje 25 do < 35 kg
At least 3 cm from your last injection site
Barem 3 cm od mjesta na kojem je ubrizgana prethodna injekcija
At least 3.6 log10 EID50 (1 dose) per animal by coarse spray, drinking water or intranasal/ocular administration.
Najmanje 3,6 log10 EID50 (1 doza) po životinji, za cijepljenje raspršivanjem, u vodi za piće ili intranazalno/okularno.
At least 32.6 kg
najmanje 32,6 kg
At least 32.6 kgb
najmanje 32,6 kgb
at least 35
Najmanje 35
At least 4 points
Poboljšanje od najmanje
At least 4 points improvement on ADAS-Cog with no worsening on CIBIC-Plus and PDS
ADAS-Cog bez pogoršanja na CIBIC-Plus i PDS
At least 40
najmanje 40
at least 5 to < 10 kg (REYATAZ
najmanje 5 do < 10 kg
at least 5 to < 10 kg (REYATAZ
Najmanje 5 do < 10 kg (REYATAZ
at least 5 to < 10 kg (REYATAZ
Najmanje 5 to < 10 kg (REYATAZ
At least 5 years of long-term follow-up was completed after treatment in 462 patients and 327 patients, respectively.
Najmanje 5 godina dugotrajnog praćenja nakon liječenja dovršila su ukupno
At least 6 cases had a positive rechallenge.
U najmanje 6 slučajeva nuspojava se ponovno javila nakon ponovnog uzimanja lijeka.
At least 6 months after prior therapy, bortezomib was started at the last tolerated dose of 1.3 mg/m2 (n=93) or ≤ 1.0 mg/m2 (n=37) and given on days 1, 4, 8 and 11 every 3 weeks for maximum of 8 cycles either as single agent or in combination with dexamethasone in accordance with the standard of care.
Najmanje 6 mjeseci nakon prethodne terapije, započela je primjena bortezomiba uz zadnju toleriranu dozu od 1,3 mg/m2 (n=93) ili ≤ 1,0 mg/m2 (n=37) te je primijenjen na 1., 4., 8. i 11. dan svaka 3 tjedna do maksimalno 8 ciklusa, bilo kao jedini lijek ili u kombinaciji s deksametazonom u skladu sa standardnim liječenjem.
At least 6 months after prior therapy, bortezomibwas started at the last tolerated dose of 1.3 mg/m2 (n=93) or ≤ 1.0 mg/m2 (n=37) and given on days 1, 4, 8 and 11 every 3 weeks for maximum of 8 cycles either as single agent or in combination with dexamethasone in accordance with the standard of care.
Najmanje 6 mjeseci nakon prethodne terapije, započela je primjena bortezomiba uz zadnju toleriranu dozu od 1,3 mg/m2 (n=93) ili ≤ 1,0 mg/m2 (n=37) te je primijenjen 1., 4., 8. i 11. dan svaka 3 tjedna do maksimalno 8 ciklusa, bilo kao jedini lijek ili u kombinaciji s deksametazonom u skladu sa standardnim liječenjem.
At least 6 months after prior therapy, VELCADE was started at the last tolerated dose of 1.3 mg/m2 (n=93) or ≤ 1.0 mg/m2 (n=37) and given on days 1, 4, 8 and 11 every 3 weeks for maximum of 8 cycles either as single agent or in combination with dexamethasone in accordance with the standard of care.
Najmanje 6 mjeseci nakon prethodne terapije, započela je primjena VELCADEa uz zadnju toleriranu dozu od 1,3 mg/m2 (n = 93) ili ≤ 1,0 mg/m2 (n = 37) te je primijenjen 1., 4., 8. i 11. dan svaka 3 tjedna do maksimalno 8 ciklusa, bilo kao jedini lijek ili u kombinaciji s deksametazonom u skladu sa standardnim liječenjem.
At least 64% of the patients treated were classified as ‘responders’, since their HbA1c levels either fell by at least 0.6% from the baseline value over the course of the studies, or their HbA1c levels were 6.1% or less at the end of the studies.
Najmanje 64 % liječenih bolesnika svrstani su u skupinu koja je pozitivno odgovorila na lijek jer im je razina HbA1c tijekom ispitivanja pala s osnovne vrijednosti za najmanje 0,6 % ili im je razina HbA1c na kraju ispitivanja bila 6,1 % ili manja.
at least 7 days before starting treatment – to make sure that you are not already pregnant every month during treatment.
najmanje 7 dana prije početka liječenja – kako bi provjerio da niste već trudni svaki mjesec tijekom liječenja.
at least 7 days before starting treatment – to make sure that you are not already pregnant every month during treatment.
najmanje 7 dana prije početka liječenja – kako bi se utvrdilo da već niste trudni svaki mjesec za vrijeme trajanja liječenja.
At least 7 days must elapse between discontinuation of Xadago and initiation of treatment with MAO inhibitors or pethidine (see section 4.3 and 4.5).
Mora proći najmanje 7 dana između prestanka liječenja lijekom Xadago i početka liječenja MAO inhibitorima ili petidinom (vidjeti dijelove 4.3 i 4.5).
At least 72 hours must pass between two consecutive doses of Bortezomib Accord.
Mora proći najmanje 72 sata između dvije uzastopne doze lijeka Bortezomib Accord.
At least 72 hours should elapse between consecutive doses of Bortezomib Accord.
Između dvije uzastopne doze Bortezomib Accorda, mora proći najmanje 72 sata.
At least 72 hours should elapse between consecutive doses of Bortezomib Accord.
Između dviju uzastopnih doza Bortezomib Accorda mora proteći najmanje 72 sata.
At least 72 hours should elapse between consecutive doses of Bortezomib Hospira.
Između dvije uzastopne doze lijeka Bortezomib Hospira mora proteći najmanje 72 sata.
At least 72 hours should elapse between consecutive doses of Bortezomib Hospira.
Između dvije uzastopne doze lijeka Bortezomib Hospira, mora proći najmanje 72 sata.
At least 72 hours should elapse between consecutive doses of Bortezomib Hospira.
Između dviju uzastopnih doza lijeka Bortezomib Hospira mora proteći najmanje 72 sata.
At least 72 hours should elapse between consecutive doses of VELCADE.
Između dvije uzastopne doze VELCADEa mora proteći najmanje 72 sata.
At least 72 hours should elapse between consecutive doses of VELCADE.
Između dvije uzastopne doze VELCADEa, mora proteći najmanje 72 sata.
At least 72 hours should elapse between consecutive doses of VELCADE.
Između dvije uzastopne doze VELCADEa, mora proći najmanje 72 sata.
At least 72 hours should elapse between consecutive doses of VELCADE.
Između dviju uzastopnih doza VELCADEa mora proteći najmanje 72 sata.
At least 75 % of an oral dose reaches the systemic circulation as the active metabolite.
Barem 75 % oralne doze u sistemsku cirkulaciju dolazi u
At least 75 % of an oral dose reaches the systemic circulation as the active metabolite.
Barem 75 % oralne doze u sistemsku cirkulaciju dolazi u obliku aktivnog metabolita.
At least 75 % of an oral dose reaches the systemic circulation as the active metabolite.
Barem obliku aktivnog metabolita.
at least annually in patients with normal renal function at least two to four times a year in patients with eGFR (creatinine clearance) at the lower limit of normal and in elderly patients.
najmanje jedanput godišnje u bolesnika s normalnom funkcijom bubrega najmanje dva do četiri puta godišnje u bolesnika s eGFR (klirens kreatinina) na donjim granicama normale i u starijih bolesnika.
at least annually in patients with normal renal function at least two to four times a year in patients with serum creatinine levels at the upper limit of normal and in elderly subjects
najmanje jedanput godišnje u bolesnika s normalnom funkcijom bubrega najmanje dva do četiri puta godišnje u bolesnika s vrijednostima kreatinina u serumu pri gornjoj granici normale i u starijih osoba
At least five doses of folic acid must be taken during the seven days preceding the first dose of pemetrexed, and dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
Bolesnici moraju uzeti najmanje pet doza folne kiseline tijekom sedam dana koji prethode prvoj dozi pemetrekseda te je moraju nastaviti uzimati za cijelog trajanja liječenja i još 21 dan nakon posljednje doze pemetrekseda.
At Least Four
Najmanje četiri
at least once a year in patients with normal renal function at least two to four times a year in patients with serum creatinine levels at or above the upper limit of normal and in elderly patients.
najmanje jedanput godišnje u bolesnika s normalnom bubrežnom funkcijom najmanje dva do četiri puta godišnje u bolesnika u kojih su razine kreatinina u serumu na gornjoj granici normalnih vrijednosti ili više te u starijih osoba.
at least once a year in patients with normal renal function at least two to four times a year in patients with serum creatinine levels at or above the upper limit of normal and in elderly patients.
najmanje jedanput godišnje u bolesnika s normalnom funkcijom bubrega najmanje dva do četiri puta godišnje u bolesnika u kojih su razine kreatinina u serumu na gornjoj granici normalnih vrijednosti ili više, te u starijih bolesnika.
at least once a year in patients with normal renal function at least two to four times a year in patients with serum creatinine levels at the upper limit of normal and in elderly patients
barem jednom godišnje u bolesnika s normalnom funkcijom bubrega barem dva do četiri puta godišnje u bolesnika u kojih su razine kreatinina u serumu na gornjoj granici normale i u starijih bolesnika
at least once a year in patients with normal renal function at least two to four times a year in patients with serum creatinine levels at the upper limit of normal and in elderly patients.
najmanje jedanput godišnje u bolesnika s normalnom funkcijom bubrega najmanje dva do četiri puta godišnje u bolesnika u kojih su razine kreatinina u serumu na gornjoj granici normale te u starijih bolesnika.
at least once a year in patients with normal renal function at least two to four times a year in patients with serum creatinine levels at the upper limits of normal and in elderly subjects
najmanje jedanput godišnje u bolesnika s normalnom funkcijom bubrega najmanje dva do četiri puta godišnje u bolesnika s povišenim vrijednostima kreatinina u serumu i u starijih bolesnika
At least once a year, your doctor will check that your kidneys are working normally.
Najmanje jednom godišnje liječnik će provjeriti rade li Vaši bubrezi normalno.
At Least One
Najmanje jedna
At least one marker from each of the following categories:
barem jedan marker iz svake od sljedećih kategorija:
At least one new vertebral fracture (0–1 year)
Najmanje jedan novi vertebralni prijelom (0-1 godina)
At least one new vertebral fracture (0–1 year)
Najmanje jedan novi vertebralni prijelom (0–1 godina)
At least one new vertebral fracture (0–2 year)
Najmanje jedan novi vertebralni prijelom (0-2 godine)
At least one new vertebral fracture (0–2 year)
Najmanje jedan novi vertebralni prijelom (0–2 godine)
At least one new vertebral fracture (0–3 year)
Najmanje jedan novi vertebralni prijelom (0-3 godine)
At least one new vertebral fracture (0–3 year)
Najmanje jedan novi vertebralni prijelom (0–3 godine)
At least one of the palivizumab resistance-associated substitutions, N262D, K272E/Q, or S275F/L was identified in these 8 clinical RSV isolates resulting in a combined resistance- associated mutation frequency of 6.3% in these patients.
U tih 8 kliničkih izolata RSV-a utvrđena je barem jedna supstitucija povezana s rezistencijom na palivizumab: N262D, K272E/Q ili S275F/L, što znači da kombinirana učestalost mutacija povezanih s rezistencijom u tih bolesnika iznosi 6,3%.
At least one year following the primary vaccination course for canine parainfluenza virus and Leptospira components .
Najmanje godinu dana nakon osnovnog cijepljenja za CPiV, komponente Leptospire. .
At least one year following the primary vaccination course for canine parainfluenza virus and Leptospira components.
Najmanje godinu dana nakon osnovnog cijepljenja za CPiV, komponente Leptospire. .
At least one year following the primary vaccination course for canine parainfluenza virus.
Najmanje godinu dana nakon osnovnog cijepljenja za CPiV.
At least one year following the primary vaccination course for CPiV and Leptospira components.
Najmanje godinu dana nakon osnovnog cijepljenja za komponente CPiV i Leptospira.
At least six months after the last injection, your child will receive an additional injection (booster).
Najmanje 6 mjeseci nakon zadnje injekcije dijete će primiti dodatnu injekciju (doza docjepljivanja).
At least three years following the primary vaccination course for CDV, CAV-1, CAV-2 and CPV.
Najmanje tri godine nakon osnovnog cijepljenja za CDV, CAV-1, CAV-2 i CPV.